Townsend & Associates Inc Lowers Stock Holdings in Pfizer Inc. $PFE

Townsend & Associates Inc lowered its position in Pfizer Inc. (NYSE:PFE) by 10.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,871 shares of the biopharmaceutical company’s stock after selling 1,001 shares during the period. Townsend & Associates Inc’s holdings in Pfizer were worth $220,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. CORDA Investment Management LLC. lifted its position in shares of Pfizer by 6.4% in the second quarter. CORDA Investment Management LLC. now owns 1,143,514 shares of the biopharmaceutical company’s stock valued at $27,719,000 after acquiring an additional 68,451 shares in the last quarter. Members Advisory Group LLC grew its position in shares of Pfizer by 2.6% during the second quarter. Members Advisory Group LLC now owns 212,296 shares of the biopharmaceutical company’s stock worth $5,146,000 after purchasing an additional 5,351 shares in the last quarter. Unison Advisors LLC raised its stake in Pfizer by 1.9% during the 2nd quarter. Unison Advisors LLC now owns 92,115 shares of the biopharmaceutical company’s stock valued at $2,233,000 after purchasing an additional 1,717 shares during the period. Mountain Capital Investment Advisors Inc. purchased a new position in Pfizer in the 2nd quarter worth approximately $200,000. Finally, Community Bank of Raymore lifted its holdings in Pfizer by 20.9% in the 2nd quarter. Community Bank of Raymore now owns 49,130 shares of the biopharmaceutical company’s stock worth $1,191,000 after purchasing an additional 8,500 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

PFE stock opened at $24.52 on Monday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.36. The firm has a market capitalization of $139.38 billion, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The company has a fifty day simple moving average of $24.89 and a two-hundred day simple moving average of $24.11. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.